IFNB1 and neoplasm: The treatment of these breast CSCs by IFN-β induces a less aggressive epithelial/non–CSC state, which is evident by the re-expression of the epithelial/non–CSC marker (CD24) and downregulation of mesenchymal markers (VIMENTIN, SLUG), concomitant with reduced abilities of cell migration and tumor-sphere formation.